FDA Approves New Cancer Treatment
The U.S. Food and Drug Administration has given the green light to a new cancer treatment tablet, Rasonque, made by Revolution Medicines in California. This pill, taken once daily, targets various forms of the RAS protein that contribute to tumor growth in pancreatic cancer.
In its statement, the FDA described Rasonque as a fresh option for patients confronting advanced pancreatic cancer. It approved the drug over six months before the scheduled review deadline.
“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” stated acting FDA Commissioner Kyle Diamantas.
The drug is authorized for adults with metastatic pancreatic cancer who did not respond to previous treatments or couldn’t undergo certain combination therapies.
Pancreatic Cancer Statistics
Pancreatic adenocarcinoma, representing a significant portion of the approximate 67,000 yearly pancreatic cancer cases in the U.S. according to the National Cancer Institute, remains one of the deadliest cancers. Despite constituting merely 3.2% of total cancer diagnoses, it leads to a high number of cancer-related deaths due to its late detection and fast spread.
Clinical Trial Results
Rasonque’s approval followed a randomized trial with 500 patients having pre-treated metastatic disease. Patients taking Rasonque showed a median overall survival of 13.2 months, significantly improving from the 6.7-month survival seen in the standard chemotherapy group.
The FDA accelerated the approval process by granting priority review, orphan drug status, and breakthrough therapy designation. The application was assessed under the FDA commissioner’s National Priority Voucher pilot program, speeding up access to vital public health treatments.
Before approval, a “safe to proceed” letter was issued, allowing expanded access to receive the drug earlier. Reported side effects during trials included rash, diarrhea, mouth sores (stomatitis), nausea, fatigue, vomiting, abdominal pain, fluid retention (edema), reduced appetite, and bleeding (hemorrhage).
“Today’s landmark approval is the most significant advance we have seen in the fight against pancreatic cancer, a devastating disease,” remarked Dr. Anna Berkenblit, chief scientific and medical officer of the Pancreatic Cancer Action Network (PanCAN).
Dr. Berkenblit expressed confidence in the drug’s potential to change the approach to treating pancreatic cancer, providing patients more time, better quality of life, and hope for further research advancements.